SHANG.FOS.PHARM.GR.H YC 1 (08HH) — Cash Flow Reinvestment Rate
SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Cash Flow Reinvestment Rate of 1.30x as of December 2025, reinvesting €6.75 Billion (capex €4.45 Billion plus investments €2.31 Billion) from operating cash flow of €5.21 Billion. Check how high is SHANG.FOS.PHARM.GR.H YC 1's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
SHANG.FOS.PHARM.GR.H YC 1 Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for SHANG.FOS.PHARM.GR.H YC 1 across 5 annual periods. Explore 08HH debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Year-by-year capital reinvestment analysis for SHANG.FOS.PHARM.GR.H YC 1. For live market cap and broader valuation context, see market cap of SHANG.FOS.PHARM.GR.H YC 1.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.30x | €6.75 Billion | €5.21 Billion | €4.45 Billion | ▲ +14.6% |
| 2024 | 1.13x | €5.06 Billion | €4.48 Billion | €4.41 Billion | ▼ -46.4% |
| 2023 | 2.11x | €7.20 Billion | €3.41 Billion | €5.34 Billion | ▼ -1.5% |
| 2022 | 2.14x | €9.04 Billion | €4.22 Billion | €5.89 Billion | ▲ +47.6% |
| 2021 | 1.45x | €5.72 Billion | €3.94 Billion | €4.97 Billion | — |